Diabetes medication gives promising results with Parkinson’s patients

Diabetes medication gives promising results with Parkinson’s patients

An exenatide injection, which is used in diabetes mellitus (type 2 diabetes), would also make the condition improve of parkinson’s patients. This is evident from a long-term initial investigation into the drug.

In The Lancet, a study published in which 60 persons with Parkinson’s disease were involved. Half of them received weekly injections of exenatide (that the blood sugar levels of diabetics helps reduce), the other half received a placebo administered.

At the beginning of the study and also after each and every twelve weeks the participants were examined and various parts of their motor abilities, assessed through a points system, including tremors (vibrations), the degree of balance and stiffness of the limbs.

Morning and evening

On the day that they were studied had the participants various exercises in the morning to do, even before they take their medication (or placebo) were taken. Then they had the exercises again in the evening run, after the administration of exenatide or placebo.

With these exercises is a total of 132 points to “earn”. People with Parkinson’s outside of this study that no further medication to take, to see after running the same test normally their “score” each year, with three points bags.

The participants in the study were over one year were investigated. The persons who are exenatide injection were showed on average an increase of 3.5 point compared to the people from the placebo group, as was discovered after sixty weeks.

Huge value

According to the authors of the study, exenatide the symptoms of the disease under control, and possibly also the course of Parkinson’s slowing. Existing complaints patients have – so far known – not reduced.

“A difference of 3.5 point is not significant, but if it turns out that this benefit is cumulative and that the number of points after a year it doubles, then the progression of the disease as possible, a halt to be called. That is a huge value,” says Thomas Foltynie, co-author of the study.

Follow us

Don't be shy, get in touch. We love meeting interesting people and making new friends.

Most popular